Dishman Carbogen Amcis Ltd.

Financial

	Dishman Carbogen Amc	Jubilant Pharmova	Biocon
Operational Metrics
API Sector
US DMF Filings	18.0 .	98.0 .	n/a
Total reactor capacity	1150.0 kL	n/a	n/a
Pharmaceutical Sector
R&D as a % of Total Sales	2.89 %	0.61 %	8.32 %
Financials
5 yr Average ROE	0.72 %	10.45 %	9.2 %
5yr average Equity Multiplier	1.49	2.05	2.34
5yr Average Asset Turnover Ratio	0.25	0.64	0.39
5yr Avg Net Profit Margin	1.79 %	8.17 %	10.15 %
Price to Book	0.63	1.98	1.89
P/E	0.0	283.16	29.87
5yr Avg Cash Conversion Cycle	42.6 Days	-3.54 Days	-81.57 Days
Inventory Days	101.13 Days	78.49 Days	82.47 Days
Days Receivable	80.42 Days	54.89 Days	91.14 Days
Days Payable	166.8 Days	167.25 Days	232.53 Days
5yr Average Interest Coverage Ratio	2.31	4.68	15.21
5yr Avg ROCE	2.38 %	10.85 %	9.08 %
5yr Avg Operating Profit Margin	20.95 %	20.24 %	27.02 %
5 yr average Debt to Equity	0.23	0.71	0.58
5yr CAGR Net Profit	n/a	n/a	-12.56 %
5yr Average Return on Assets	0.54 %	5.11 %	4.23 %
Shareholdings
Promoter Holding	59.32 %	50.68 %	60.64 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	0.0	-0.03 %
Change in Mutual Fund Holding (3 Yrs)	-6.64 %	1.49 %	6.06 %

Business

	Dishman Carbogen Amc	Jubilant Pharmova	Biocon
Product Wise Break-Up	Product Wise Break-Up Contract Research & Contract Manufacturing (CRAMS) 77.7 Cholesterol & Vit D Analogues 9.4 API 8.5 Quats & Generics 4.4 Marketable Molecules 0 0 Radiopharmaceuticals 0 Allergy therapy products 0 Active pharmaceutical ingredients 0 India Branded pharmaceuticals 0 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 0 Solid dosage formulations 0 Generics 0 Novel 0 Biosimilars 0 Syngene (Research Services) 0 Branded Formulations 0 Biologics 0	Product Wise Break-Up Marketable Molecules 0 Quats & Generics 0 Solid dosage formulations 11.58 Branded Formulations 0 Cholesterol & Vit D Analogues 0 0 Active Pharmaceutical Ingredient (API) 10.08 Specialty intermediates 0 API 0 India branded pharmaceuticals 0.57 Generics 0 Nutritional products 0 Radiopharmaceuticals 40.74 Life science chemicals 0 Biosimilars 0 Syngene (Research Services) 0 Novel 0 Contract Research and Development Services 8.37 Contract Manufacturing 18.57 Anti-allergic 9.69 Biologics 0 Others 0.4	Product Wise Break-Up Marketable Molecules 0 Quats & Generics 0 Solid dosage formulations 0 Branded Formulations 0 Cholesterol & Vit D Analogues 0 0 Active pharmaceutical ingredients 0 Specialty intermediates 0 API 0 India Branded pharmaceuticals 0 Generics 17.41 Nutritional products 0 Radiopharmaceuticals 0 Life science chemicals 0 Biosimilars 61.46 Syngene (Research Services) 21.13 Novel 0 0 0 Allergy therapy products 0 Biologics 0
Segment Break-Up	Segment Break-Up Carbogen Amcis 52.32 CDMO Sterile Injectables 0 Generics 0 Allergy Immunotherapy 0 Radiopharma 0 Proprietary Novel Drugs 0 0 Life Science Ingredients 0 Pharmaceuticals 0 Others 47.68	Segment Break-Up Generics 11.69 Allergy Immunotherapy 10.13 Life Science Ingredients 0 Proprietary Novel Drugs 0 Radiopharma 44.22 Drug discovery and development solutions 15.49 Pharmaceuticals 0 CDMO Sterile Injectables 18.47 Carbogen Amcis 0	-
Location Wise Break-Up	Location Wise Break-Up Rest of the World 98.29 India 1.71 China 0 Americas and Europe 0 Ireland 0 USA 0	Location Wise Break-Up USA 0 Americas and Europe 89.61 India 2.39 Rest of the World 8.0 Ireland 0 China 0	Location Wise Break-Up USA 37.08 Americas and Europe 0 India 14.98 Rest of the World 37.4 Ireland 10.55 China 0
Operating Profit Break-Up	Operating Profit Break-Up Generics 0 CDMO Sterile Injectables 0 Allergy Immunotherapy 0 Radiopharma 0 Proprietary Novel Drugs 0 Contract Research and Development 0 Life Science Ingredients 0 Pharmaceuticals 0 Others 100	Operating Profit Break-Up Generics 0 Allergy Immunotherapy 24.76 Life Science Ingredients 0 Proprietary Novel Drugs 0 Radiopharma 58.92 Contract Research and Development 9.18 Pharmaceuticals 0 CDMO Sterile Injectables 7.13 Others 0.01	Operating Profit Break-Up Generics 6.09 Allergy Immunotherapy 0 Life Science Ingredients 0 Proprietary Novel Drugs 0 Radiopharma 0 Contract Research and Development 0 Pharmaceuticals 0 CDMO Sterile Injectables 0 Others 93.91
Therapeutic Area Break-Up	Therapeutic Area Break-Up Non-APIs / Intermediates 31.68 Oncology 20.79 Ophthalmology 17.82 Hormones 13.86 Pain Management 3.96 Blood Related 3.96 Antibiotics 3.96 ADC-Warhead / ADC 3.96 Others 0.01	-	-

Dishman Carbogen Amcis Ltd.

Dishman Carbogen Amcis Ltd.

SIGN UP FOR FREE